ScreenerHero

ORGO Organogenesis Holdings Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · organogenesis.com
1.280USD-3.03%Mkt Cap: 164.70M $P/E: —

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced w…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.13BUSDP/E 24.9
TAK
Takeda Pharmaceutical Company Limited
$59.16BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.78BUSDP/E 65.4
GALD
Galderma Group AG
$43.33BUSDP/E 56.1
HLN
Haleon plc
$40.72BUSDP/E 18.9
SDZ
Sandoz Group AG
$34.23BUSDP/E 59.2
HLN
Haleon plc
$32.92BUSDP/E 19.1
ZTS
Zoetis Inc.
$30.20BUSDP/E 12.0
UTHR
United Therapeutics Corporation
$22.85BUSDP/E 19.1
VTRS
Viatris Inc.
$20.03BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.06BUSDP/E 110.0
NBIX
Neurocrine Biosciences, Inc.
$14.36BUSDP/E 20.7
IPN
Ipsen S.A.
$12.68BUSDP/E 22.9
ELAN
Elanco Animal Health Incorporated
$11.26BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.16BUSDP/E 27.7
KRK
Krka, d. d.
$8.71BUSDP/E 19.4
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1
HLUN-B
H. Lundbeck A/S
$6.66BUSDP/E 11.8
ALKS
Alkermes plc
$6.73BUSDP/E 105.6
HIMS
Hims & Hers Health, Inc.
$6.55BUSD

Key Statistics

Company
Market Cap164.70M USD
Enterprise Value333.14M USD
Revenue (TTM)457.45M USD
Gross Profit425.51M USD
Net Income (TTM)37.03M USD
Revenue/Share3.59 USD
Last Price1.280 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees854
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.32
PEG—
EV/EBITDA-34.34
EV/Revenue0.73
P/S0.38
P/B1.16
EPS (TTM)-0.83
EPS (Forward)-0.31
52W Range
1.2501% of range7.077
52W High7.077 USD
52W Low1.250 USD
Profitability
Gross Margin75.57%
Oper. Margin-119.25%
EBITDA Margin-2.12%
Profit Margin6.58%
ROE8.53%
ROA6.19%
Growth
Revenue Growth-56.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.31M USD
CapEx (TTM)14.15M USD
FCF Margin6.22%
FCF Yield17.27%
Net Debt20.85M USD
Net Debt/EBITDA-2.15
Balance Sheet
Debt/Equity0.19
Current Ratio3.52
Quick Ratio2.58
Book Value/Sh1.15 USD
Cash/Share0.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.000 USD
Upside (mean)+56.3%
Target Range2.000 USD – 2.000 USD
# Analysts1
Ownership
Shares Out.128.67M
Float61.06M
Insiders44.56%
Institutions51.68%
Short Interest
Short Ratio21.0d
Short % Float17.26%
Short % Out.10.97%
Shares Short14.12M
Short (prev mo.)14.23M
Technical
SMA 501.752 (-26.9%)
SMA 2002.737 (-53.2%)
Beta1.27
S&P 52W Chg16.45%
Avg Vol (30d)696.60K
Avg Vol (10d)647.78K
Technical Indicators
RSI (14)29.7
MACD-0.1370
MACD Signal-0.1494
MACD Hist.+0.0124
BB Upper1.600 USD
BB Middle1.421 USD
BB Lower1.243 USD
BB Width25.11%
ATR (14)0.0878 USD
Vol Ratio (20d)1.06x